Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients
Nov 9, 2026, 9:38 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Positive single-cell signals (immune activation, CD8 EM expansion, tumor apoptosis pathway changes) could support expansion of pelareorep into multiple myeloma and thus long-term revenue potential if corroborated by clinical efficacy; confirmation requires clinical response and safety data.
AI summary
What happened, with direct paths to the underlying reporting
Oncolytics reported single-cell translational data showing pelareorep remodels the tumor microenvironment and induces innate/adaptive antiviral immune activation in heavily pretreated relapsed/refractory multiple myeloma; results will be presented at ASH on Dec 12, 2026.
Single-cell sequencing demonstrates pelareorep’s ability to remodel the tumor microenvironment in heavily pretreated relapsed/refractory multiple myeloma.
These translational data will be presented at the 68th ASH Annual Meeting (Abstract No. 2183) on December 12, 2026 as a poster.
There were notable increases in populations of CD8 effector memory (CD8 EM) T cells and upregulation of genes linked to T cell activation, antiviral activity, and cytotoxic function.
Multiple myeloma cells exhibited increased apoptotic and p53 signaling and reduced MYC pathway activity, indicating direct biological effects on tumor cells.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Oncolytics Biotech announced a 19.5-month median response duration for pelareorep in colorectal cancer, significantly outperforming historical benchmarks. This data, alongside a p…
StockNews.AISignal intelligence